StockData
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. (SPRO) stock

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3042% below fair value
$0.90−0.05 (-4.77%)

Close on Nov 17, 2026Market cap $52.49MP/E 22.5Yield –

Spero Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Spero Therapeutics's price to book ratio was 1.3× on Nov 11, 2026, against 5.1× a year earlier. Over the last 5 years it ranged from 0.4× to 5.1×, with a median of 1.4×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.3×−3.6
2025Dec 31, 20255.0×+4.1
2024Dec 31, 20240.9×−0.6
2023Dec 29, 20231.5×−0.8
2022Dec 30, 20222.3×−2.3
2021Dec 31, 20214.6×+0.8
2020Dec 31, 20203.8×+1.9
2019Dec 31, 20191.9×+1.0
2018Dec 31, 20180.9×–

More Spero Therapeutics figures

See a number that looks wrong?